Where to buy Adipotide.

You can buy Adipotide from research-supply vendors online, and that's effectively the only route. No pharmacy compounds it and no regulator has approved it. So where to buy Adipotide comes down to which vendor can prove the vial holds the full chimeric construct. Adipotide isn't a metabolic peptide. It's a cytotoxic construct that kills the cells lining fat-tissue blood vessels.

Research compounds

Referenced in this guide

Batch-matched COAHPLC + mass specResearch use only

Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.

Browse the catalog

• CoA. Certificate of Analysis. A one-page lab report showing the specific lot’s purity, identity, and water content.
• ISO/IEC 17025. The international quality standard for testing labs. A 17025-accredited lab has been audited by a third party for technical competence.
• Chimeric peptide. A single synthetic molecule assembled from two functionally distinct sequences. Here that's a targeting domain and a cytotoxic payload, joined by a short linker.
• Homing sequence. A short peptide selected to bind a receptor enriched on one tissue, used to steer a payload there. Adipotide’s was identified by in vivo phage display.
• D-amino acid. The mirror-image form of a natural amino acid. D-residues resist protease digestion, which is why the killer domain uses them, and why chirality has to be verified analytically.
• Lyophilized. Freeze-dried into a stable powder. Lyophilized peptides survive shipping at room temperature for short periods and store for years frozen.

Where can you buy Adipotide?

Adipotide reaches buyers through research-supply vendors and effectively nowhere else. Compounding pharmacies don't supply it, because it has no approved indication anywhere and carries a documented organ-toxicity signal. A third grey channel exists, built on the 2011 media cycle rather than on any newer science.

• Research-supply vendors, effectively the only channel. Nearly all Adipotide moves here. The vendor sells lyophilized powder labeled for laboratory research use only, which is legal under US law. It isn't legal for human use, and the vendor isn't a pharmacy.
• Compounding pharmacies, not a realistic route. A 503A pharmacy compounds prescription preparations for individual patients. Adipotide doesn't appear on FDA's bulk-substance lists for compounding. In practice no US compounder supplies it, and a vendor implying otherwize is describing a channel that doesn't exist.
• Grey-channel resellers working the 2011 media cycle. The primate results generated a large consumer media wave and durable demand that outlived the science. The tell is a product page that cites 2011 enthusiastically and says nothing about what happened after it.

Verify five things before ordering from the first channel. A third-party CoA from a named ISO 17025-accredited lab. HPLC purity with the chromatogram attached. Mass-spec identity for the full construct. Disulfide-cyclization confirmation. Chiral verification of the killer domain.

Anything less is a purity number attached to an unproven identity. Resellers on the third channel usually reproduce the body-weight-reduction figure while omitting the renal signal reported in the same body of work.

Which research-supply vendors to shortlist

Five vendors, ordered the way our supplier comparison orders them — on what each one will show you rather than what it claims — with every column pulled from the vendor's own storefront on 13 August 2026; there is no verified Adipotide price anywhere in that set, so pricing is benchmarked on BPC-157 across the same vendors and no price column appears here.

† Behemoth Labz publishes real certificates, but the newest genuine document we could open was dated 2024-08-08 — roughly two years old, which for a construct this fragile is the difference that matters. Stock varies by compound, so confirm a vendor actually lists Adipotide before you compare — what these columns describe is disclosure practice, and that is the part that travels across every compound a vendor sells. Disclosure: this site earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to. Every column above is a document you can open or a page you can load yourself.

We hold no verified CAS number for Adipotide, and this is one compound where a registry lookup would not settle identity anyway — so ask the vendor for mass-spec identity of the full chimeric construct, confirmation that the disulfide cyclization is closed, and chiral verification of the killer domain, on a certificate whose lot number matches the vial.

What is Adipotide?

Adipotide was built by Renata Pasqualini and Wadih Arap's groups, originally at MD Anderson Cancer Center and now at the Rutgers Cancer Institute of New Jersey. The design is unusually legible for a peptide. One end is an address. The other end is a weapon.

The address is CKGGRAKDC, a nine-residue cyclic sequence found by in vivo phage display because it binds prohibitin on the surface of white-adipose-tissue endothelial cells. Prohibitin is normally a mitochondrial protein. Its surface presentation on adipose vasculature is the biological quirk the sequence exploits.

The weapon is D(KLAKLAK)₂, a 14-residue D-amino acid sequence developed to disrupt mitochondrial membranes and trigger apoptosis once the peptide is internalized. A Gly-Gly linker joins them. Written out, the whole molecule is CKGGRAKDC-GG-D(KLAKLAK)₂.

That architecture puts Adipotide in a different category from everything else in a weight-management catalog. It doesn't modulate satiety, doesn't act on incretin receptors, and doesn't slow gastric emptying. It ablates adipose-tissue blood supply by killing endothelial cells, and the overlying tissue regresses with the vasculature. The conceptual neighbor is anti-angiogenic oncology, not metabolic pharmacology.

The signature preclinical work is old. Kolonin and colleagues established targeted adipose ablation in rodents in Nature Medicine in 2004, per Kolonin et al., 2004.

Barnhart and colleagues extended it to obese rhesus macaques in Science Translational Medicine in 2011, reporting roughly 11% body-weight reduction over four weeks alongside improved insulin sensitivity. That's Barnhart et al., 2011. The same primate work flagged renal toxicity. Both papers predate the 2020–2026 literature window, and nothing since has advanced the original construct toward human use.

That pattern repeats. A 2020 imaging study coupled the same CKGGRAKDC sequence to iron-oxide nanoparticles to build a brown-adipose-tissue MRI probe, per Hu et al., 2021. Again the homing sequence is a research tool, not the front end of a cytotoxic therapeutic.

Across the whole 2020–2026 window, only three PubMed-indexed papers mention the homing sequence at all. None of them is a clinical trial of Adipotide as an obesity therapy.

We'd read that as a signal about what the material is defensibly for in 2026. Prohibitin-binding work, apoptosis-pathway work, and comparator use against the newer delivery constructs. It isn't a signal that a stalled therapeutic quietly succeeded off-index.

How do you verify Adipotide before you buy?

Four checks are materially sharper for a chimeric construct like Adipotide. Treat identity as a triad of sequence, mass and chirality. Demand disulfide-cyclization data. Demand chiral verification of the killer domain. Read the price as a proxy for synthesis risk. Our eight general criteria apply on top.

1. Identity is a triad, not a CAS lookup

Older single-domain research peptides are identified on a CoA by a CAS Registry Number. Adipotide isn't reliably identified that way. It's a chimeric peptide-drug conjugate, referenced in the literature by sequence and by the name FTPP rather than by one widely-published registry entry.

The practical identity triad is sequence, mass, and chirality. Mass-spec should be consistent with the calculated mass of the full construct, around 2611 g/mol.

Two failure modes are worth naming. A mass near the homing fragment alone means the conjugation failed. A mass near the killer fragment alone means the vial holds an untargeted cytotoxic peptide. Both can co-exist with a respectable purity number, because purity and identity are different questions.

2. The disulfide is load-bearing

CKGGRAKDC binds prohibitin only in its cyclic form, closed by the Cys2–Cys9 disulfide. Break that bond and the targeting function is gone. What remains is an apoptosis payload with no address. This is the most consequential attribute on an Adipotide CoA and the one most often missing from vendor paperwork.

A credible report shows cyclization explicitly. A free-thiol assay result, a mass difference of two daltons versus the reduced form, or both.

It should also carry the handling consequence. The disulfide is reduction-sensitive, so reducing agents such as DTT, BME, TCEP or glutathione will cleave it in solution and abolish the homing function. A vendor who publishes the storage window but never mentions reducing agents hasn't thought about the molecule they're selling.

3. Chirality in the killer domain

D(KLAKLAK)₂ is built from D-amino acids specifically so the payload resists protease digestion. Substituting the natural L-form is cheaper, invisible on a standard reversed-phase HPLC purity trace, and produces material with a different stability profile from the published compound.

The check is a chiral HPLC report, or an amino-acid analysis confirming D-composition across the 14-residue killer domain. Vendors who supply it say so plainly. Vendors who don't describe purity in general terms and change the subject.

4. Synthesis complexity is a quality risk you're pricing

Twenty-five residues, a cyclization step, and fourteen D-residues stack three independent sources of batch variance into one molecule. Incomplete cyclization, partial epimerization and deletion sequences at the linker are all realistic outcomes of a rushed run.

None of them announces itself on a headline purity figure. That's why the Adipotide market has a floor a simpler peptide doesn't, and why we treat the cheap end of the range as diagnostic rather than as a bargain.

What does Adipotide cost in 2026?

Adipotide costs $85–$180 for the standard 10 mg vial and $55–$110 for 5 mg at third-party tested retail. It's expensive to make, and unlike most catalog peptides the cost is defensible rather than a markup story.

• 5 mg vial: $55–$110, or $11–$22 per mg. Uncommon entry size, and per-mg cost is worst here.
• 10 mg vial: $85–$180, or $8.50–$18 per mg. The standard retail size and the best per-mg value at most vendors.
• Multi-vial discounts: 10–20% off on 3-packs. Narrower than the discounts on simpler peptides, because the underlying synthesis cost doesn't compress much with volume.

Compare that to a short linear peptide, which routinely clears at $3–$8/mg. The Adipotide premium isn't vendor positioning. It's the cyclization step, the D-amino acid raw materials, and the extra analytical work needed to prove both.

Material offered below roughly $45 per 10 mg vial deserves a direct question about which of those steps was skipped. Above $25/mg, the pricing has left synthesis cost behind and is carrying retail markup. In between, price is a weak quality signal on its own, and the CoA contents are the real discriminator.

Is Adipotide legal to buy?

Yes. Adipotide is legal to buy and sell in the US as a research reference compound labeled for laboratory use only. It isn't approved for any indication and isn't a controlled substance. Selling it for human consumption is illegal.

• United States, FDA: Not approved for any indication. Phase I work exists in an oncology population only. Not a controlled substance. Legal as a research reference compound labeled for laboratory use only.
• European Union, EMA: Not approved.
• WADA: Not explicitly listed on the Prohibited List. See the WADA Prohibited List for current categorizations.
• Major sports leagues: Not explicitly prohibited.

The research-use-only designation does real work here, and we'd treat it as substance rather than boilerplate. Our page on what “research use only” actually means covers the mechanics.

For a compound with a documented organ-toxicity signal and no approved indication anywhere, RUO labeling isn't a technicality a vendor works around. It's the entire legal basis on which the material can be sold at all.

Handling framing follows from the mechanism. Adipotide's payload is designed to kill cells, with theoretical off-target apoptotic potential on cardiac, hepatic and renal endothelium. Credible suppliers indicate cytotoxic handling on the vial and in the documentation. A vendor whose Adipotide listing reads exactly like their recovery-peptide listing hasn't adjusted for what's in the vial.

What are the red flags when buying Adipotide?

Eight Adipotide warning signs we’d walk away from.

• No disulfide-cyclization data on the CoA. The reduced form doesn’t bind prohibitin. A purity number without cyclization confirmation doesn’t establish that the material is Adipotide.
• No chiral verification of D(KLAKLAK)₂. L-substitution is cheaper and invisible on a standard reversed-phase purity trace. Ask for chiral HPLC or amino-acid analysis by name.
• Mass-spec matching a fragment rather than the construct. A mass near either domain alone means conjugation failed. The report should be consistent with the full 2611 g/mol chimeric molecule.
• Obesity marketing built on 2011 while omitting the renal signal. The primate study that produced the body-weight-reduction figure reported the kidney toxicity too. Quoting one without the other is selective, not informative.
• “Adipose-ablation peptide” positioning alongside GLP-1 products. Shelving a cytotoxic anti-vasculature agent next to incretin agonists as if they were interchangeable is a category error a serious supplier doesn’t make.
• Pricing far under the market band. On a molecule with three stacked synthesis risks, a steep discount usually reflects a skipped QC step rather than an efficiency.
• No cytotoxic-handling indication. Documentation that never distinguishes this material from an ordinary research peptide suggests the supplier hasn’t characterized what they’re shipping.
• Silence on reducing agents. Storage guidance that omits DTT, BME, TCEP and glutathione is guidance written for a generic peptide, not this one.

Adipotide

10 mg ≥99% pure Lyophilized

10 mg lyophilized powder in a 3 mL glass vial, ≥99% HPLC. Lyophilized stability −20 °C for 24 months or 2–8 °C for 6 months; reconstituted in bacteriostatic water the in-use window is 14 days at 2–8 °C, and reducing agents must be avoided so the homing-domain disulfide stays intact. Batch-matched third-party COA by QR code on every vial. Research use only.

Learn more

Frequently asked questions

Is Adipotide legal to buy in the USA?

Yes, as a research reference compound labeled for laboratory use only. Adipotide isn't FDA-approved and isn't a controlled substance. Selling it for human consumption is illegal. Acquiring it as research material is not. That distinction is the entire legal basis for the compound's availability, which is why RUO labeling here isn't decorative.

What should an Adipotide Certificate of Analysis show?

Six things. Purity by HPLC with the chromatogram attached. Mass-spec consistent with the 2611 g/mol chimeric construct. Explicit disulfide-cyclization confirmation for the CKGGRAKDC domain. Chiral verification of D-composition in the killer domain. Karl Fischer water content. Counterion content.

The testing lab must be ISO 17025-accredited and named on the report. Our guide to reading a Certificate of Analysis covers the general fields. The three chimeric-specific ones above are what you add for this compound.

Why did Adipotide’s development stall?

Renal toxicity. The primate work that produced the body-weight-reduction headline also reported a kidney signal. The compound clears renally, and the D(KLAKLAK)₂ payload carries non-target apoptotic potential on renal tissue.

A Phase I trial in obese prostate-cancer patients was registered as NCT01477580 but produced no peer-reviewed efficacy publication in the 2020–2026 window. Development for obesity hasn't advanced in the fifteen years since.

The clinical success of the incretin class removed most of the remaining incentive to revisit a cytotoxic approach. The full accounting is in our complete Adipotide research guide.

Does Adipotide have a CAS number?

Not one that functions as a practical buyer check, the way CAS numbers do for older single-domain peptides. Adipotide is a chimeric construct referenced in the literature by sequence and by the FTPP name.

Sequence, mass and chirality are the identity triad on a CoA. A report that leads with a CAS field but omits disulfide and chirality data is verifying the least informative attribute available.

Why is the Adipotide disulfide bond such a big deal?

Because the homing function depends on it. CKGGRAKDC binds prohibitin in its cyclic form. Without the Cys2–Cys9 disulfide the address is gone and only the payload remains. Reduced or scrambled material can still return a respectable HPLC purity figure while being functionally a different molecule. It's also why reducing agents are excluded from the reconstitution and handling guidance.

How does Adipotide compare to the GLP-1 class?

They're different classes of molecule with non-comparable evidence bases. Incretin receptor agonists are metabolic modulators with completed, published Phase III programs and FDA approvals in obesity. Adipotide is a cytotoxic anti-vasculature agent with zero completed Phase II or Phase III trials and a documented renal signal.

For context on what the incretin literature actually contains, see our GLP-1 class comparison. The two aren't substitutable in a research design, and Adipotide is not an alternative to an approved agent in any supervised context.

Is Adipotide banned by WADA?

Adipotide isn't explicitly listed on the Prohibited List and isn't explicitly prohibited by the major leagues. That isn't the same as being cleared. WADA maintains catch-all provisions covering substances without current regulatory approval for human therapeutic use, and Adipotide has no approval anywhere. Anyone subject to testing should read the current list directly rather than infer clearance from absence.

Why is Adipotide so much more expensive than a comparable-length peptide?

Three stacked cost drivers. Twenty-five residues is a longer chain than most catalog peptides. The homing domain requires a disulfide cyclization step. Fourteen of the residues are D-amino acids, which cost more as raw materials and require chiral analytics to verify.

Each one also adds a way for a batch to fail QC. Our guide to the underlying chemistry is how peptides are made.